Journal of the Pediatric Infectious Diseases Society
In Utero Exposure to Dolutegravir-Based Antiretroviral Therapy Alters Growth and Metabolic Outcomes
Abstract Background Approximately 5,000 women living with HIV give birth each year, with perinatal transmission occurring in less than 1% of cases. The World Health Organization (WHO) recommends dolutegravir (DTG) as first and second line antiretroviral therapy (ART), readily crossing the placenta, resulting in persistent exposure throughout development. In adults, DTG-based ART has been linked to metabolic changes, including alterations in bone mineral density and body composition. The effects of DTG exposure on b …